Selected Articles from This Issue

Abstract

Highlights| September 06 2022 Selected Articles from This Issue Author & Article Information Online ISSN: 1538-8514 Print ISSN: 1535-7163 ©2022 American Association for Cancer Research2022American Association for Cancer Research Mol Cancer Ther (2022) 21 (9): 1369. https://doi.org/10.1158/1535-7163.MCT-21-9-HI Related Content A commentary has been published: Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma A commentary has been published: YES1: A Novel Therapeutic Target and Biomarker in Cancer A commentary has been published: PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design View more A commentary has been published: Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 6 2022 Citation Selected Articles from This Issue. Mol Cancer Ther 1 September 2022; 21 (9): 1369. https://doi.org/10.1158/1535-7163.MCT-21-9-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Targeted therapies have been a breakthrough in the management of cancer. YES1, a SRC family kinase (SFK) member, has recently emerged as a druggable target in solid tumors. Here, Garmendia and colleagues review the most relevant roles and the molecular circuitry of YES1 in cancer and summarize the efficacy of SFK inhibitors in preclinical and clinical trials. YES1 is overexpressed and amplified in many solid tumors; it is also a biomarker of poor prognosis and predicts response to some SFK inhibitors. YES1 promotes tumor growth and metastasis. Available data strongly support YES1 as a novel therapeutic target in solid cancers. Epithelial malignancies are the most commonly occurring cancers. The central involvement of protease-activated-receptors (PARs) a subgroup of G-protein coupled-receptors (GPCRs) in tumor growth and progression is becoming acknowledged. Nag and colleagues have identified a pleckstrin-homology (PH)-binding motif within PAR4, as in PAR1 and PAR2 family members.... You do not currently have access to this content.